2,5-dichloro-4-bromophenol (B 2)

RN given refers to parent cpd

Also Known As:

B 2; 2,5-dichloro-4-bromophenol, calcium salt; 2,5-dichloro-4-bromophenol, diethanolamine salt; 2,5-dichloro-4-bromophenol, monoethanolamine salt; 2,5-dichloro-4-bromophenol, potassium salt; 2,5-dichloro-4-bromophenol, sodium salt; phebrol; sodium 2,5-dichloro-4-bromophenol; 4-bromo-2,5-dichlorophenol

Networked: 889 relevant articles (31 outcomes, 80 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        Chlorophenols: 95
        2,5-dichloro-4-bromophenol: 889
        Chlorobenzenes: 5
        Chlorophenols: 95
        2,5-dichloro-4-bromophenol: 889

Experts

1.	Couture, Réjean: 9 articles (01/2012 - 04/2002)
2.	Zamri-Saad, Mohd: 8 articles (02/2022 - 06/2015)
3.	Calixto, J B: 8 articles (01/2013 - 10/2001)
4.	Bader, Michael: 8 articles (10/2011 - 12/2002)
5.	Ibrahim, Hayder Hamzah: 6 articles (07/2019 - 06/2015)
6.	Marza, Ali Dhiaa: 6 articles (07/2019 - 06/2015)
7.	Omar, Abdul Rahman: 6 articles (07/2019 - 10/2013)
8.	Zamri-Saad, M: 6 articles (06/2019 - 10/2006)
9.	Calixto, João B: 6 articles (12/2012 - 12/2002)
10.	Ongali, Brice: 6 articles (12/2005 - 04/2002)

Related Diseases

1.	Hemorrhagic Septicemia (Haemorrhagic Septicemia) 12/01/2007 - "Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves." 08/18/2012 - "Efficacy of intranasal vaccination of field buffaloes against haemorrhagic septicaemia with a live gdhA derivative Pasteurella multocida B:2." 03/01/2005 - "Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration." 06/02/2011 - "The objective of this study was to investigate the haemolytic and cytotoxic activity of Pasteurella multocida B:2 strains, originally from cases of haemorrhagic septicaemia in cattle. " 09/01/2023 - "The isolate was not found to be haemorrhagic septicaemia (HS) specific B:2 by the PCR assay. "
2.	Pain (Aches) 03/01/2012 - "In addition, pretreatment or co-injection with B(2)R antagonist dramatically reduced the pain-related licking behavior induced by BK injection. " 04/01/2014 - "Pain intensity was measured on a 100-mm non-graduated visual analogue scale (VAS), and it was significantly greater in group A (8 mm) than that in group B (2 mm). " 01/01/1991 - "Comparing the percentage of dysmenorrhoea it emerges: 1) that dysmenorrhoea is present in a lower percentage in subjects in Group A (68.19%) in respect to women in Group B; 2) that in a considerable number of girls in Group B it was observed that there was a regression or an improvement in the pain symptomatology after the beginning in athletic activity; 3) dysmenorrhoea was much less in the more intense the sports activity (Groups C and D). " 10/01/2019 - "Median (IQR) procedure pain score was less in group A 2 (1-2) than in group B 2 (2-3); P = 0.001. " 10/01/2011 - "[Twenty-one cases of pain caused by earthquake treated mainly with acupuncture at Jiaji (EX-B 2)]."
3.	Neoplasms (Cancer) 04/01/1991 - "Histopathologic evaluations revealed that a) SMC had no effect; b) 2- and 5-day T cells, injected at E:T ratios greater than 5:1, caused significant reduction in tumor size; and c) 2- or 5-day T cells, at a 40:1 E:T ratio, resulted in little or no histologic evidence of tumor. " 02/10/2023 - "Among them, garxanthochin B (2) demonstrated moderate inhibitory activities against five human cancer cell types, with IC50 values of 14.71~24.43 μM. " 01/01/2023 - "Both aaptolobamines A (1) and B (2) show broad bioactivity, including cytotoxicity against cancer cell lines, moderate antimicrobial activity against a methicillin-resistant strain of Staphylococcus aureus, and weak activity against a Pseudomonas aeruginosa strain. " 01/01/2021 - "NLNs were resected in 4 patients in group A and B; 2 of them involved by the tumor. " 08/29/2020 - "The anti-inflammatory results showed that at a concentration of 10 µg/mL, 6 and 8 inhibited the production of IL-1β to 68 ± 1 and 56 ± 1%, respectively, in LPS-stimulated murine macrophages J774A.1. Furthermore, sardigitolide B (2) displayed cytotoxicities toward MCF-7 and MDA-MB-231 cancer cell lines with the IC50 values of 9.6 ± 3.0 and 14.8 ± 4.0 µg/mL, respectively."
4.	Inflammation (Inflammations) 05/21/2020 - "This study adopted a targeted isolation approach to the discovery and analysis of five 9,11-secosteroids, including two novel compounds named sinleptosterols A (1) and B (2) as well as five known analogues (8αH-3β,11-dihydroxy-24-methylene-9,11-secocholest-5-en-9-one (3), 8βH-3β,11-dihydroxy-24-methylene-9,11-secocholest-5-en-9-one (4), leptosterol A (5), (24S)-3β,11-dihydroxy-24-methyl-9,11-secocholest-5-en-9-one (6), and 3β,11-dihydroxy-9,11-secogorgost-5-en-9-one (7)) in terms of 1H-NMR patterns and potency against neutrophilic inflammation. " 01/01/2013 - "Our results suggest that, in the absence of B(2)R, both B(1)R and AT(2)R play important compensatory roles in preventing deterioration of cardiac function and remodelling post-MI possibly via suppression of inflammation, TGFβ(1) and ERK1/2 signalling." 05/01/2010 - "Treatment with a selective B(2)R agonist initiated at the time of induction of acute MI in mice had a beneficial effect on cardiac function, tissue remodeling, and inflammation-related tissue gene expression, which may explain its structural and functional benefits." 01/01/2013 - "Blockade of AT(2)R or B(1)R worsened cardiac remodelling, hypertrophy and dysfunction associated with increased inflammation and ERK1/2 phosphorylation and decreased NO excretion in B(2)R(-/-) mice, which were exacerbated by dual blockade of B(1)R and AT(2)R. " 05/01/2003 - "In various animal models and in humans it has been shown that the stimulation of BK B(2) receptors is not only implicated in the pathogenesis of inflammation, pain and tissue injury but also in powerful cardioprotective mechanisms. "
5.	Stroke (Strokes) 01/01/2011 - "The results presented here will serve as priors for the design of further studies to test the efficacy of the concept with stroke patients, and the found effects will provide a basis for the development of a classifier for a future B(2)RI." 10/01/2006 - "The aim of the current study was therefore to investigate the effect of delayed B(2) receptor inhibition on morphological and functional outcome following experimental stroke. " 04/01/2014 - "In group A 6 (3.5%) patients developed stroke where as in group-B 2 (1.5%) patients developed stroke out of these 6 patients there were 2 mortalities after stroke in group-A while in group-B there was no mortality after stroke within 30 days postoperatively. " 02/01/2010 - "The patterns and densities of PAR(2) and B(2) immunoreactivity in frozen MCA sections were not altered with stroke. " 02/15/2005 - "Hospital mortality for stroke was higher in Group A (12/627: 1.91%) than in Group B (0/761; p<0.001) as well as the incidence of non-fatal stroke (Group A 12/627: 1.91% versus Group B 2/761: 0.26% p=0.006). "

Related Drugs and Biologics

1.	Bradykinin
2.	Kinins
3.	icatibant
4.	Proteins (Proteins, Gene)
5.	Vaccines
6.	azaphenothiazine
7.	Thromboxanes
8.	Prostaglandins
9.	Glucose (Dextrose)
10.	LF 16-0687

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Lung Transplantation
4.	Microspheres (Microsphere)
5.	Therapeutics